Skip to main content
Online First
ADCETRIS™ (brentuximab vedotin) for the Treatment of Relapsed/Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
Read More
Online First
Patient Management With ADCETRIS™: An Advanced Practice Oncology Nurse Roundtable Discussion
Ellen Neylon, RN, BSN, CCPR, OCN, Stephanie Thompson, NP-C, MSN, RN, Amanda Copeland, MSN, RN, CNS
Read More
Brother, Can You Spare Some Chemotherapy? No End in Sight for Drug Shortages
Timothy G. Tyler, PharmD, FCSHP, FHOPA
Read More
Original Research
Ifosfamide Neurotoxicity in Pediatric Patients: A Multi-Institutional Case Series Report
Amy Lee, MD, David W. Henry, MS, RPh, BCOP, FASHP, John Szechung Ng, PharmD, Kerry Parsons, PharmD, BCOP, Betsy Bickert Poon, PharmD, FCCP, Jeff Schwartz, MD, Tara Smith, PharmD, Chatchawin Assanasen, MD
Read More
Perspective
Dosing Chemotherapy in Obese Patients: No Clear Answers, Yet
Scott Soefje, PharmD, BCOP
Read More
From the Literature
Concise Reviews from the Literature Relevant to Hematology Oncology Pharmacy
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
Read More
Original Research
Carboplatin Dosing in Overweight and Obese Patients: A Single-Center Experience
Ginah Nightingale, PharmD BCOP, James A. Trovato, PharmD, MBA, BCOP, FASHP, Myounghee Lee, PhD, PharmD, Jennifer Thompson, PharmD, BCOP
Read More
Perspective
Ipilimumab: A New Era in Metastatic Melanoma Management
Timothy G. Tyler, PharmD, FCSHP, FHOPA
Read More
FDA Updates
Reversible Posterior Leukoencephalopathy Syndrome Secondary to Bevacizumab
Diana Pinto, PharmD, William Kernan, PharmD, BCPS, James Hoffman, MD, Mohammed Ibrahim, PharmD, CRPH, BCOP, BCPS, Bruno Bastos, MD
Read More
Original Research
The Risk of Neurotoxicity with Concomitant Use of Aprepitant and Ifosfamide
Anthony Jarkowski III, PharmD, BCOP, Austin Miller, PhD, Tammy A. Hecke, RN, BSN, Leona Blustein, PharmD, Michael K.K. Wong, MD, PhD, FRCPC
Read More
Page 191 of 197
Results 1901 - 1910 of 1964